Advertisement

Somatostatin pp 183-192 | Cite as

Somatostatin and Depression

  • David R. Rubinow
  • Robert M. Post
  • Candace Davis
  • Allen Doran
Part of the Serono Symposia, USA book series (SERONOSYMP)

Abstract

Much evidence supports a role for somatostatin as a modulator of central nervous system (CNS) activity and indirectly suggests the relevance of somatostatin to several neuropsychiatric disorders, particularly depression.

Keywords

Depressed Patient Schizophrenic Patient Affective Illness Nerve Termin Psychopharmacologic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brownstein M, Arimura A, Stao H, Schally AV, Kizer JS. The regional distribution of somatostatin in the rat brain. Endocrinology 1975; 96: 1456–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Johannson O, Hokfelt T. Thyrotropin releasing hormone, somatostatin and enkephalin: distribution studies using immunohistochemical techniques. J Histochem Cytochem 1980; 28: 364–6.CrossRefGoogle Scholar
  3. 3.
    Srikant CB, Patel YC. Somatostatin receptors. Adv Exp Med Biol 1985; 188: 291–304.PubMedCrossRefGoogle Scholar
  4. 4.
    Leroux P, Quirion R, Pelletier G. Localization and characterization of brain somatostatin receptors as studied with somatostatin-14 and somatostatin-28 receptor radioautography. Brain Res 1985; 347: 74–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Renaud LP, Martin JB, Brazeau P. Depressant action of TRH, LH-RH and somatostatin on activity of central neurons. Nature 1975; 255: 233–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Delfs JR, Dichter MA. Effects of somatostatin on mammalian cortical neurons in culture: physiological actions and unusual dose response characteristics. J Neurosci 1983; 3: 1176–88.PubMedGoogle Scholar
  7. 7.
    Reichlin S. Systems for the study of regulation of neuropeptide secretion. In: Martin JB, Reichlin S, Bick KL, eds. Neurosecretion and brain peptides. New York: Raven Press, 1981.Google Scholar
  8. 8.
    Reichlin S. Somatostatin in the nervous system. In: Schmitt FO, Bird SJ, Blood FE, eds. Molecular genetic neuroscience. New York: Raven Press, 1982.Google Scholar
  9. 9.
    Gillin JC, Sitaram N, Wehr T, et al. Sleep and affective illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1983.Google Scholar
  10. 10.
    Davis GC, Buchsbaum MS, Naber D, et al. Altered pain perception and CSF endorphins in psychiatric illness. Ann NY Acad Sci 1982; 398: 36–373.CrossRefGoogle Scholar
  11. 11.
    Weingartner H, Silberman EK. Cognitive changes in depression. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1983.Google Scholar
  12. 12.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Cortical administration of somatostatin (SRIF): effect on sleep and motor behavior. Pharmacol Biochem Behav 1976; 5: 73–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Havlicek V, Rezek M, Friesen H. Somatostatin and thyrotropin releasing hormone: central effect on sleep and motor system. Pharmacol Biochem Behav 1976; 4: 455–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Aponte G, Leung P, Gross D, Yamada T. Effects of somatostatin on food intake in rats. Life Sci 1984; 35: 741–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Lotter EC, Woods SC. Somatostatin decreases food intake. Diabetes 1977; 26 (suppl 1): 358.Google Scholar
  16. 16.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Central site of action of somatostatin (SRIF): role of hippocampus. Neuropharmacology 1976; 15: 499–504.PubMedCrossRefGoogle Scholar
  17. 17.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Behavioural and motor excitation and inhibition induced by the administration of small and large doses of somatostatin into the amygdala. Neuropharmacology 1977; 16; 157–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Havlicek V, Rezek M, Leybin L, Friesen H. Analgesic effect of cerebral ventricular administration of somatostatin (SRIF). Fed Proc 1977; 36: 363.Google Scholar
  19. 19.
    Meynadier J, Chrubasik J, Dubar M, Wunsch E. Intrathecal somatostatin in terminally ill patients. A report of two cases. Pain 1985; 23: 9–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Vecsei L, Kiraly C, Bollok I, et al. Comparative studies with somatostatin and cysteamine in different behavior tests on rats. Pharmacol Biochem Behav 1984; 21: 833–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Walsh TJ, Emerich DF, Winokur A, Banki C, Bissette G, Nemeroff CB. Intrahippocampal injection of cysteamine depletes somatostatin and produces cognitive impairments in the rat. Soc Neuroscience Abstr 1985; 11: 621.Google Scholar
  22. 22.
    Patel YC, Rao K, Reichlin S. Somatostatin in human cerebrospinal fluid. N Engl J Med 1977; 296: 529–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Gram JJ, Edwardson J, Millard PH. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontology 1981; 27: 216–23.CrossRefGoogle Scholar
  24. 24.
    Dupont E, Christensen SE, Hansen AP, Olivarius B deF, Orskov H. Low cerebrospinal fluid somatostatin in Parkinson’s disease: an irreversible abnormality. Neurology 1982; 32: 312–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B, Agid Y. Somatostatin and dementia in Parkinson’s disease. Brain Res 1983; 278: 376–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NPV. Reduced lumbar CSF somatostatin in Alzheimer’s disease. Life Sci 1982; 31: 2073–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Serby M, Richardson SB, Twente S, Siekierski J, Corwin J, Rotrosen J. CSF somatostatin in Alzheimer’s disease. Neurobiol Aging 1984; 5: 187–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Sorensen KV, Christensen SE, Dupont E, Hansen AP, Pedersen E, Orskov H. Low somatostatin content in cerebrospinal fluid in multiple sclerosis. Acta Neurol Scand 1980; 61: 186–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Beal MF, Mazurek MF, Black PMcL, Martin JB. Human cerebrospinal somatostatin in neurologic disease. J Neurol Sci 1985; 71: 91–104.PubMedCrossRefGoogle Scholar
  30. 30.
    Davies P. Neurotransmitters in Alzheimer’s disease. Read before the International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, April 1, 1981.Google Scholar
  31. 31.
    Soininen HS, Jolkkonen JT, Reinikainen KJ, Halonen TO, Riekkinen PJ. Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci 1984; 63: 167–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE. Somatostatin immunoreactivity in neuritic plaques of Alzheimer’s patients. Nature 1985; 314: 90–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Roberts GW, Crow TJ, Polak JM. Localization of neuronal tangles in somatostatin neurones in Alzheimer’s disease. Nature 1985; 314: 92–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Tamminga CA, Foster NL, Chase TN. Reduced brain somatostatin levels in Alzheimer’s disease. N Engl J Med 1985; 313 (20): 1294–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238: 298–302.PubMedCrossRefGoogle Scholar
  36. 36.
    Rubinow DR, Gold PW, Post RM, et al. CSF somatostatin in affective illness. Arch Gen Psychiatry 1983; 40: 409–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Black PM, Ballantine HT, Carr DB, Beal MF, Martin JB. Beta-endorphin and somatostatin concentrations in the cerebrospinal fluid of patients with depressive disorder [Abstract]. 39th Annual Convention of the Society of Biological Psychiatry, 1984; 135: 177.Google Scholar
  38. 38.
    Agren H, Lundgvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 1984; 9: 233–48.PubMedCrossRefGoogle Scholar
  39. 39.
    Bissette G, Walleus H, Widerlov E, et al. Reductions of cerebrospinal fluid concentrations of somatostatin-like immunoreactivity (SRIF-LI) in dementia, major depression and schizophrenia [Abstract]. Abstracts of the 14th Annual Meeting of the Society for Neuroscience, vol 10 (part 2 ), 1984; 11: 1093.Google Scholar
  40. 40.
    Doran A, Rubinow D, Roy A, Pickar D. CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients. Arch Gen Psychiatry 1986; 43: 365–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ, Kizer JS. Regional brain concentrations of neuropeptides in Huntington’s chorea and schizophrenia. Science 1983; 221: 972–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Ferrier IN, Cross AJ, Johnson JA, et al. Neuropeptides in Alzheimer type dementia. J Neurol Sci 1983; 62: 159–70.PubMedCrossRefGoogle Scholar
  43. 43.
    Sorensen KV. Rapid post-mortem decomposition of the somatostatin cells in human brain. An immunohistochemical examination. Biomed Pharmacother 1984; 38: 458–61.PubMedGoogle Scholar
  44. 44.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington, DC: APA, 1981.Google Scholar
  45. 45.
    Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986; 21: 341–65.PubMedCrossRefGoogle Scholar
  46. 46.
    Knigge KM, Bennett-Clarke C, Burchanowski B, Joseph SA, Romagnano MA, Sternberger LA. Relationships of some releasing-hormone-producing neuron systems to the ventricles of the brain. In: Motta M, ed. Endocrine functions of the brain. New York: Raven Press, 1980.Google Scholar
  47. 47.
    Weindl A, Sofroniew MB. Relation of neuropeptides to mammalian circumventricular organs. In: Martin JB, Reichlin S, Bick KL, eds. Advances in biochemical psychopharmacology. New York: Raven Press, 1982.Google Scholar
  48. 48.
    Wehr TA. Biological rhythms and manic-depressive illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders, vol 1. Baltimore: Williams and Wilkins, 1984.Google Scholar
  49. 49.
    Berelowitz M, Perlow MJ, Hoffman HJ, Frohman LA. The diurnal variation of immunoreactive thyrotropin-releasing hormone and somatostatin in the cerebrospinal fluid of the rhesus monkey. Endocrinology 1981; 109: 2102–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Arnold MA, Reppert SM, Rorstad OP, et al. Temporal patterns of somatostatin in the cerebrospinal fluid of the rhesus monkey: effect of environmental lighting. J Neurosci 1982; 2: 674–80.PubMedGoogle Scholar
  51. 51.
    Vecsei L, Bollok I, Telegdy G. Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats. Peptides 1983; 4: 293–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 1976; 33: 1039–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973; 28: 19–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Gibbons JL. Cortisol secretion rates in depressive illness. Arch Gen Psychiatry 1964; 10: 572–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free cortisol excretion in depression. J Psychol Med 1976; 6: 43–50.CrossRefGoogle Scholar
  56. 56.
    Heisler S, Reisine T, Hook V, Axelrod J. Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and adrenocorticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci USA 1982; 79: 6502–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Brown MR, Rivier C, Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology, 1984; 114: 1546–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Serby M, Richardson SB, Rypma B, Twente S, Rotrosen JP. Somatostatin regulation of the CRF-ACTH-cortisol axis. Biol Psychiatry 1986 (in press).Google Scholar
  59. 59.
    Aguila MC, McCann SM. The influence of hGRF, CRF, TRH and LHRH on SRIF release from median eminence fragments. Brain Res 1985; 348: 180–2.PubMedCrossRefGoogle Scholar
  60. 60.
    Katakami H, Arimura A, Frohman LA. Involvement of hypothalamic somatostatin in the suppression of growth hormone secretion by central corticotropin-releasing factor in conscious male rats. Neuroendocrinology 1985; 41: 390–3.PubMedCrossRefGoogle Scholar
  61. 61.
    Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology 1985; 117: 2478–82.PubMedCrossRefGoogle Scholar
  62. 62.
    Wolkowitz OM, Rubinow DR, Breier A, Doran AR, Pickar D. Steroid effects in normals: a prospective study. 139th Annual Meeting of the American Psychiatric Association, Washington, DC, 1986.Google Scholar
  63. 63.
    Post RM, Ballenger JC, Uhde TW, Bunney WE. Efficacy of carbamazepine in manic-depressive illness: implications for underlying mechanisms. In: Neurobiology of mood disorders, vol 1. Baltimore: Williams and Wilkins, 1984.Google Scholar
  64. 64.
    Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S. Effect of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology 1985; 85: 210–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Beal MF, Martin JB. Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity, Neurosci Lett 1984; 47: 125–30.PubMedCrossRefGoogle Scholar
  66. 66.
    Gattaz WF, Rissler K, Gattaz D, Cramer H. Effects of Haloperidol on somatostatin-like immunoreactivity in the CSF of schizophrenic patients. Psychiatry Res 1986; 17: 1–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Higuchi T. Neuropeptides and amygdaloid kindling. In: Wada JA, ed. Kindling III. New York: Raven Press, 1985.Google Scholar
  68. 68.
    Kato N, Higuchi T, Friesen HG, Wada JA. Changes of immunoreactive somatostatin and B-endorphin content in rat brain after amygdaloid kindling. Life Sci 1983; 32: 2415–22.PubMedCrossRefGoogle Scholar
  69. 69.
    Higuchi T, Kokubu T, Sikand GS, Wada JA, Friesen HG. A study of somatostatin receptors in amygdaloid-kindled rat brain. J Neurochem 1984; 43: 1271–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Havlicek V, Friesen HG. Comparison of behavioural effects of SRIF and B-endorphin in animals. In: Collu R, Barbeau A, Rochefort JG, Ducharm JR, eds. Central nervous system effects of hypothalamic hormones and other peptides. New York: Raven Press, 1979.Google Scholar
  71. 71.
    Iofee S, Havlicek V, Friesen HG, Chernick V. Effect of iontophoretically applied somatostatin (SRIF) on cortical neurons in awake unanesthetized animals. Fed Proc Abstrc 1977; 36: 364.Google Scholar
  72. 72.
    Higuchi T, Sikand GS, Kato N, Wada JA, Friesen HG. Profound suppression of kindled seizures by cysteamine: possible role of somatostatin to kindled seizures. Brain Res 1983; 288: 359–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • David R. Rubinow
    • 1
  • Robert M. Post
    • 1
  • Candace Davis
    • 1
  • Allen Doran
    • 1
  1. 1.National Institute of Mental HealthBethesdaUSA

Personalised recommendations